Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | CCR8 | P51685 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18838334 | 0.93 | KDM4E (0.55) | KDM4EPKMUSP30GPR119CCR8 | |
| SCHEMBL18838335 | 0.87 | USP30 (0.53) | KDM4EPKMUSP30GPR119CCR8 | |
| SCHEMBL19995750 | 0.82 | STS (0.48) | KDM4EPKMGPR119KMT2AMEN1 | |
| SCHEMBL18838379 | 0.81 | STS (0.51) | KDM4EPKMGPR119TSHRALOX15 | |
| SCHEMBL13199301 | 0.81 | KDM4E (0.68) | KDM4EPKMUSP30GPR119CCR8 | |
| SCHEMBL20951857 | 0.78 | EPHX1 (0.46) | GPR119NAMPT | |
| SCHEMBL18860270 | 0.77 | CARM1 (0.48) | KMT2AMEN1 | |
| SCHEMBL20461031 | 0.76 | EPHX1 (0.45) | GPR119TSHRNAMPT | |
| SCHEMBL4921150 | 0.76 | USP30 (0.71) | KDM4EPKMUSP30CCR8KMT2A | |
| SCHEMBL4924196 | 0.76 | USP30 (0.71) | KDM4EPKMUSP30CCR8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | KDM4E 2152/4885PKM 2309/4885USP30 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.